In May of this year, Recursion transferred the REC-994 program to the Alliance. Now, we have an exciting opportunity to delve deeper into the data from the trials and better understand encouraging trends and what factors may influence positive patient responses to the drug.
This kind of research takes time and funding. We need to raise $50k to drive the program for the next year. Thankfully, a generous donor has offered to match $25k if we can raise the other 25k before September 30! This is our chance to advance the REC-994 program and keep the door open to future clinical trials.
Will you help us keep the momentum of REC-994?
